



SGC 20TH ANNIVERSARY SYMPOSIUM
ACCELERATING DRUG DISCOVERY THROUGH OPEN SCIENCE
Chelsea Hotel (Mountbatten Salon), Toronto, Canada
March 8-9, 2023
<https://www.thesgc.org/sgc-20th-anniversary-symposium>

March 8. [12 pm - 6 pm]

Welcome:	Cheryl Arrowsmith
12:00-12:10 pm	Chief Scientist, SGC-Toronto, University of Toronto, Princess Margaret Cancer Centre
Session 1:	<i>Tackling emerging infectious diseases</i> Hosted by University of Toronto's Emerging and Pandemic Infections Consortium (EPIC), Chaired by Natasha Christie-Holmes, Director, Strategy & Partnerships
12:10-12:45 pm	<i>The Discovery of Paxlovid</i> Dafydd Owen , Pfizer
12:45-1:10 pm	<i>Identification of CSNK2 as a host kinase target for inhibition of coronavirus replication</i> Tim Willson , SGC-UNC, U of North Carolina at Chapel Hill
1:10-1:35 pm	<i>How SARS-CoV-2 changed research in Canada: a tale of CANCOV, RECLAIM and Long COVID</i> Angela Cheung , University Health Network, Sinai Health, University of Toronto
1:35-1:50 pm	<i>Abstract talk: A Target Engagement Assay to Assess Uptake, Potency, and Retention of Antibiotics in Living Bacteria</i> Rebeka Fanti , SGC-Toronto, Department of Molecular Genetics, University of Toronto
1:50 - 2:20 pm	Coffee Break
Session 2:	<i>Chemical Probes, a gateway to new medicines</i> Hosted by the Ontario Institute for Cancer Research (OICR), Chaired by Laszlo Radvanyi, President and Scientific Director
2:20-2:45pm	<i>Discovery and development of WDR inhibitors</i> Rima Al-awar , OICR
2:45-3:10pm	<i>Targeting the human kinome</i> Stefan Knapp , SGC-Frankfurt, Goethe University Frankfurt
3:10-3:45pm	<i>Development of high-affinity structure-validated binders of the Huntington's disease protein</i> Rachel Harding , SGC-Toronto, Department of Pharmacology & Toxicology, University of Toronto
3:45-4:00 pm	<i>Abstract talk: Development and preliminary characterization of a uniquely selective, first-class, publicly available chemical probe for the understudied citron kinase</i> Jesse Coker , Center for Therapeutics Discovery, Lerner Research Institute, Cleveland Clinic
4:00 - 6:00 pm	Poster Session and Networking Reception

March 9. [9 am - 4 pm]

Session 3:	<i>Probing the human (epi)genome for therapeutic opportunities</i> Hosted by Princess Margaret Cancer Centre, Chaired by Brad Wouters, Executive VP Science and Research, University Health Network	
9:00-9:25 am	<i>Regulation of Endogenous Retroelements as an Emerging Vulnerability and Therapeutic Opportunity in Cancer Treatment and Interception</i>	Daniel De Carvalho, Princess Margaret Cancer Centre
9:25-9:50 am	<i>Targeting epigenetic regulation in clear cell renal cell carcinoma reveals PRMT1 as a novel target</i>	Joe Walton, Princess Margaret Cancer Centre
9:50-10:05 am	<i>Abstract talk: Investigation of the role of the epigenetic regulator, protein arginine methyltransferase 3 (PRMT3), in cancer stem cell populations</i>	Ravinder K Bahia, Department of Cell Biology and Anatomy, University of Calgary
10:05-10:20 am	<i>Abstract talk: Suppressing cancer stem cell functions in colon tumors by antagonizing dopamine transporter</i>	Yannick D. Benoit, Department of Cellular and Molecular Medicine, University of Ottawa
10:20 - 10:50 am	Coffee Break	
Session 4:	<i>New tools for targeted protein degradation</i> Chaired by Sujata Sharma, Director, Structural & Protein Sciences, Janssen R&D	
10:50-11:15 am	<i>Interrogation of the GID4 interactome with PFI-7</i>	Dominic Owens, SGC-Toronto, Department of Pharmacology & Toxicology, University of Toronto
11:15-11:40 am	<i>A novel E3 handle for degradation of NSD2</i>	David Nie, Princess Margaret Cancer Centre, SGC-Toronto
11:40-11:55 am	<i>Abstract talk: DCAF12: a new addition to the repertoire of ubiquitin ligases for Targeted Protein Degradation</i>	Germannia Righetto, SGC-Toronto, Department of Pharmacology & Toxicology, University of Toronto
11:55am-12:10pm	<i>Abstract talk: PROTAC Virtual Screening Benchmark</i>	Evianne Rover, SGC-Toronto, Department of Pharmacology & Toxicology, University of Toronto
12:10 - 13:10 pm	Lunch Break	

Session 5:		
<i>Initiatives to accelerate drug discovery and enhance data reproducibility</i>		
Chaired by Anke Mueller-Farnow, Chair of the Board of SGC		
1:10-1:35 pm	<i>The Chemical Probes Portal, a free, public online resource of expert reviews and evaluations of chemical probes</i>	Susanne Mueller-Knapp , SGC-Frankfurt, Goethe University Frankfurt
1:35-1:50 pm	<i>CACHE: setting the stage for a breakthrough in computational hit finding</i>	Matthieu Schapira , SGC-Toronto, Department of Pharmacology & Toxicology, University of Toronto
1:50-2:15 pm	<i>YCharOS: Antibody characterization through open science</i>	Peter McPherson , SGC-Neuro, McGill University & YCharOS
2:15-2:30 pm	<i>Abstract talk: Scalable Generation of Predictive Binding Models Based on DEL Screening Data</i>	Matthew Clark , X-Chem Inc.
2:30 - 3:00 pm Coffee Break		
Session 6:		
<i>Looking toward the Future: Industry partnerships to support drug discovery</i>		
Hosted by Ontario Genomics, Chaired by Bettina Hamelin, President and CEO		
3:00-3:25 pm	<i>Target 2035: WDR proteins as a technology test-bed for illuminating the dark proteome</i>	Levon Halabelian , SGC-Toronto, Department of Pharmacology & Toxicology, University of Toronto
3:25-3:50 pm	<i>SGC-Promega collaborations: Co-developing novel reagents for target engagement in cells</i>	Matt Robers , Promega
3:50-4:00 pm	<i>Looking to the future: SGC and Target 2035</i>	Aled Edwards , SGC CEO, Department of Molecular Genetics, University of Toronto